A venture capital firm that was founded in 2020 with general partners based in the USA has a $100M USD fund dedicated to early-stage life science ventures from Seed to Series A. The initial size of investment ranges from $1-5M and the firm seeks to invest in up to 10-12 early-stage life science companies worldwide.
The firm operates under a model that differs from traditional venture capital. As a way of de-risking, the firm works closely with a CRO that provides services and guidance on clinical translation and regulatory approval to therapeutics and medical device portfolio companies. The firm also works very closely with founders. As a critical criterion, the firm prefers to assign a highly experienced CEO to their portfolio company as they strongly believe in the importance of the management team. Also, the firm mostly exits through licensing to large pharma, medtech, or services companies. They are opportunistic about other exit strategies such as IPO.
The firm focuses on therapeutics, diagnostics, and digital health. The firm will not consider digital health. For therapeutics, pre-IND products of all modalities are considered. Within diagnostics, all modalities with proof of concept are considered. The firm will consider opportunities in any indication area.
The firm prefers asset-centric products and focuses on the scientific merits of the product or technology. The firm has a strict vetting process done by a highly experienced team and prefers companies with IP in place. The firm acts as a lead and co-investor and will require board seating.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment